Stockreport

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases [Yahoo! Finance]

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF — New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for Use in Fibrotic Diseases of the Liver, including PSC— [Read more]